Granite Point Capital Management, L.P. Immunic, Inc. Transaction History
Granite Point Capital Management, L.P.
- $0
- Q3 2023
Shares
2 transactions
Others Institutions Holding IMUX
# of Institutions
64Shares Held
56.1MCall Options Held
4.7KPut Options Held
311K-
Avidity Partners Management LP Dallas, TX8.9MShares$13.9 Million0.49% of portfolio
-
Bvf Inc San Francisco, CA8.9MShares$13.9 Million0.3% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT7.29MShares$11.4 Million0.82% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$11 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.59MShares$8.73 Million0.01% of portfolio
About IMMUNIC, INC.
- Ticker IMUX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,565,000
- Market Cap $47.7M
- Description
- Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...